ScoreWhy is Beryl Drugs Ltd ?
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 10.21% and Operating profit at 5.06% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.75
2
Flat results in Dec 25
- NET SALES(9M) At Rs 13.84 cr has Grown at -20.14%
- PBDIT(Q) Lowest at Rs -0.20 cr.
- PBT LESS OI(Q) Lowest at Rs -0.61 cr.
3
Stock is technically in a Bearish range
- The technical trend has deteriorated from Mildly Bearish on 20-May-26 and has generated -5.42% returns since then
- Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
4
Below par performance in long term as well as near term
- Along with generating -2.51% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Beryl Drugs for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Beryl Drugs
16.75%
-0.04
63.75%
Sensex
-5.12%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.22%
EBIT Growth (5y)
9.30%
EBIT to Interest (avg)
0.94
Debt to EBITDA (avg)
2.51
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.58
Tax Ratio
27.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.35%
ROE (avg)
5.66%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
27
Industry P/E
34
Price to Book Value
1.15
EV to EBIT
13.57
EV to EBITDA
5.63
EV to Capital Employed
1.13
EV to Sales
0.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.63%
ROE (Latest)
4.25%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
PBDIT(Q)
Highest at Rs 1.34 cr.
PBT LESS OI(Q)
Highest at Rs 0.87 cr.
PAT(Q)
Highest at Rs 0.56 cr.
EPS(Q)
Highest at Rs 1.10
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Beryl Drugs
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1.34 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.87 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 0.56 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 1.10
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
